TSRL, Inc. Presents at the Cutting Edge/Drug Discovery & Development in Michigan Symposium

Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, has presented on various topics at the Cutting Edge/Drug Discovery & Development in Michigan Symposium September 9th and 10th.

Eric Simon, PhD presented on the "Development of an LC-MS Assay for Measurement of of Intracellular Concentrations of Cidofovir Prodrug USC-505 and its Metabolites". Shyamala Ganesan, PhD presented on "Improved Intracellular Concentrations of Cidofovir Diphosphate Using an Oral Prodrug Approach". Andrew Hertig, MBA, presented on "The Preclinical Accelerator: A New Model for Drug Development".

Presentations are available for viewing here:

LC-MS Method for Measuring Cidofovir Prodrugs Poster

Intracellular Conversion of Cidofovir Prodrugs Poster

Preclinical Accelerator Model for Drug Development Poster

About TSRL, Inc.

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, elipka@tsrlinc.com.

Having Fun and Helping the Local Community

Ann Arbor, Michigan, June 26th, 2015: Members of our team at TSRL, Inc. visited the Foundations Preschool of Washtenaw County (http://www.foundations-preschool.org/) last Friday for our annual Day of Caring. The weather couldn't have been better as we were put to work scrubbing floors, ripping out weeds, and staining decks. One of our team members even got a bee sting. They are okay--with the help of an onion to reduce the swelling--and the hard work was worth it for everybody. We were able to make our community preschool a cleaner, happier place for the at-risk children who need a place to learn and grow.

Looking forward to next time!

Learn more about United Way/Day of Caring: http://www.wuway.org/node/778

About Foundations Preschool:

Foundations Preschool prepares children from low income families for future academic and social success while providing their parents opportunities for professional, personal and parental growth.

We Accomplish This By Providing:

• A focus on the needs of low-income families
• Tuition subsidies based on household income
• A researched-based curriculum and teaching methods
• Professional and educated staff
• Opportunities to strengthen parenting skills through monthly workshops and a true parent/school team approach
• Speech/language/social work assessments and intervention services
• On-site dental screenings and varnishes
• Vision and auditory screenings
• Free breakfast, lunch and afternoon snack

TSRL, Inc Presents at the 28th International Conference on Antiviral Research

Ann Arbor, Michigan, May 14th, 2015: TSRL Inc., a pharmaceutical company developing novel anti-infective therapeutics in areas of high unmet medical need, is pleased to announce that Elke Lipka, PhD, MBA, has presented at the 28th International Conference on Antiviral Research (ICAR) in Rome, Italy. The presentation, entitled "Potent Broad Spectrum Anti-DNA Viral Activity for HPMPA and HPMPC Tyrosinamide Prodrugs", reports on the broad spectrum antiviral activity of acyclic nucleoside phosphonates (ANPs) as useful agents in the treatment of many DNA virus infections.

The full poster presentation can be accessed here.

About TSRL, Inc.

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL, Inc. Announces Appointment of President

Ann Arbor, Michigan, September 11th, 2014: Therapeutic Systems Research Laboratories, (TSRL), Inc. is pleased to announce the appointment of Dr. Elke Lipka as President of TSRL and Member of the Board of Directors. Dr. Lipka succeeds the late Dr. John Hilfinger, who led the company over the past ten years, transitioning its focus from formulation development to prodrug design and delivery. Dr. Lipka, who has served as Vice President of Business Development since 2007, has played a pivotal role in the development of TSRL’s existing assets and the evaluation of new project and growth opportunities. She is an experienced drug development professional with 20 year of experience in the pharmaceutical industry including at Warner-Lambert, Esperion Therapeutics and Pfizer. Dr. Lipka holds a PhD from Goethe University, Frankfurt, Germany and an MBA from the University of Michigan.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL Announces Receipt of $4.2 Million in New SBIR Funding

Ann Arbor, Michigan, June 24th, 2014: Therapeutic Systems Research Laboratories, Inc. (TSRL), announced today that the company was awarded two Phase I and one Phase II Small Business Innovation Research (SBIR) grants from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grants are supporting the preclinical research of the company’s broad-spectrum antiviral prodrug program, as well as the development of an antiviral therapeutic for the treatment of adenovirus infections. TSRL will be receiving up to $4.2 million over the next 3 years through these SBIR grants. In addition, initial manufacturing scale up of a lead candidate and preclinical pharmacology testing has been performed for TSRL by NIAID under the NIAID preclinical services contracts program.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President for Business Development, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL, Inc. Announces Agreement with Software Licensee

Ann Arbor, Michigan, June 12th, 2014: Therapeutic Systems Research Laboratories, (TSRL), Inc. announced today that it has entered into a Termination and Non-Assertion Agreement (the “Agreement”) with Simulations Plus, Inc., a California corporation (“SLP”). Under the terms of the Agreement, SLP and TSRL agreed to terminate the Exclusive Software Licensing Agreement, under which TSRL licensed to SLP Software Technology and Databases in return for royalty payments. SLP will pay TSRL a total consideration of $6 million.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President of Business Development, 734 663-4233 x236, elipka@tsrlinc.com.